Literature DB >> 18267241

Clinical genetics of Parkinson's disease and related disorders.

Christian Wider1, Zbigniew K Wszolek.   

Abstract

Our knowledge regarding the genetics of Parkinson's disease (PD) and parkinsonism has evolved dramatically during the past decade, with the discovery of numerous loci and genes. The LRRK2 gene has emerged as the most commonly involved in both familial and sporadic PD. Several variants in LRRK2 and SNCA have been associated with an increased risk of sporadic PD. PRKN, PINK1 and DJ1 mutations cause early-onset recessively inherited PD. Autosomal dominant dementia and parkinsonism is caused by mutations in the MAPT gene, and in the most recently discovered PGRN gene.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18267241     DOI: 10.1016/S1353-8020(08)70007-5

Source DB:  PubMed          Journal:  Parkinsonism Relat Disord        ISSN: 1353-8020            Impact factor:   4.891


  10 in total

Review 1.  Using stem cells and iPS cells to discover new treatments for Parkinson's disease.

Authors:  Oliver Cooper; Penny Hallett; Ole Isacson
Journal:  Parkinsonism Relat Disord       Date:  2012-01       Impact factor: 4.891

2.  Parkinson disease: calcium channel blockers and Parkinson disease.

Authors:  Ronald F Pfeiffer
Journal:  Nat Rev Neurol       Date:  2010-04       Impact factor: 42.937

Review 3.  Are there common biochemical and molecular mechanisms controlling manganism and parkisonism.

Authors:  Jerome A Roth
Journal:  Neuromolecular Med       Date:  2009-09-16       Impact factor: 3.843

Review 4.  Parkinson's disease: fetal cell or stem cell-derived treatments.

Authors:  Arnar Astradsson; Tipu Z Aziz
Journal:  BMJ Clin Evid       Date:  2015-04-21

Review 5.  Lipid rafts and neurodegeneration: structural and functional roles in physiologic aging and neurodegenerative diseases.

Authors:  Sara Grassi; Paola Giussani; Laura Mauri; Simona Prioni; Sandro Sonnino; Alessandro Prinetti
Journal:  J Lipid Res       Date:  2019-12-23       Impact factor: 5.922

6.  Manganese-induced toxicity in normal and human B lymphocyte cell lines containing a homozygous mutation in parkin.

Authors:  Jerome A Roth; Balakrishnan Ganapathy; Andrew J Ghio
Journal:  Toxicol In Vitro       Date:  2012-07-26       Impact factor: 3.500

7.  Parkinsonian phenotype in Machado-Joseph disease (MJD/SCA3): a two-case report.

Authors:  Conceição Bettencourt; Cristina Santos; Paula Coutinho; Patrizia Rizzu; João Vasconcelos; Teresa Kay; Teresa Cymbron; Mafalda Raposo; Peter Heutink; Manuela Lima
Journal:  BMC Neurol       Date:  2011-10-24       Impact factor: 2.474

8.  Glutathione S-transferase omega genes in Alzheimer and Parkinson disease risk, age-at-diagnosis and brain gene expression: an association study with mechanistic implications.

Authors:  Mariet Allen; Fanggeng Zou; High Seng Chai; Curtis S Younkin; Richard Miles; Asha A Nair; Julia E Crook; V Shane Pankratz; Minerva M Carrasquillo; Christopher N Rowley; Thuy Nguyen; Li Ma; Kimberly G Malphrus; Gina Bisceglio; Alexandra I Ortolaza; Ryan Palusak; Sumit Middha; Sooraj Maharjan; Constantin Georgescu; Debra Schultz; Fariborz Rakhshan; Christopher P Kolbert; Jin Jen; Sigrid B Sando; Jan O Aasly; Maria Barcikowska; Ryan J Uitti; Zbigniew K Wszolek; Owen A Ross; Ronald C Petersen; Neill R Graff-Radford; Dennis W Dickson; Steven G Younkin; Nilüfer Ertekin-Taner
Journal:  Mol Neurodegener       Date:  2012-04-11       Impact factor: 14.195

9.  Glutamate ionotropic receptor NMDA type subunit 2A (GRIN2A) gene polymorphism (rs4998386) and Parkinson's disease susceptibility: A meta-analysis.

Authors:  Gaurav Nepal; Jessica Holly Rehrig; Rajeev Ojha
Journal:  Aging Med (Milton)       Date:  2019-07-23

10.  New animal models of progressive neurodegeneration: tools for identifying targets in predictive diagnostics and presymptomatic treatment.

Authors:  R Andrew Tasker; Amber L Adams-Marriott; Christopher A Shaw
Journal:  EPMA J       Date:  2010-06-09       Impact factor: 6.543

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.